4 AJPSVol11559-5741
4 AJPSVol11559-5741
4 AJPSVol11559-5741
net/publication/303830731
CITATIONS READS
35 1,460
6 authors, including:
Some of the authors of this publication are also working on these related projects:
All content following this page was uploaded by Sandeep Karki on 02 September 2016.
H O S T E D BY
Available online at www.sciencedirect.com
ScienceDirect
j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / a j p s
Review
A R T I C L E I N F O A B S T R A C T
Article history: Pharmaceutical scientists throughout the world are trying to explore thin films as a novel
Received 21 April 2016 drug delivery tool. Thin films have been identified as an alternative approach to conven-
Accepted 12 May 2016 tional dosage forms. The thin films are considered to be convenient to swallow, self-
Available online 6 June 2016 administrable, and fast dissolving dosage form, all of which make it as a versatile platform
for drug delivery. This delivery system has been used for both systemic and local action via
Keywords: several routes such as oral, buccal, sublingual, ocular, and transdermal routes. The design
Thin film of efficient thin films requires a comprehensive knowledge of the pharmacological and phar-
Film-forming polymer maceutical properties of drugs and polymers along with an appropriate selection of
Mechanical properties manufacturing processes. Therefore, the aim of this review is to provide an overview of the
Manufacturing critical factors affecting the formulation of thin films, including the physico-chemical prop-
Characterization erties of polymers and drugs, anatomical and physiological constraints, as well as the
characterization methods and quality specifications to circumvent the difficulties associ-
ated with formulation design. It also highlights the recent trends and perspectives to develop
thin film products by various companies.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
* Corresponding author. College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Republic of Korea.
Tel.: +82 2 820 5606; fax: +82 2 816 7338.
E-mail address: jaehwi@cau.ac.kr (J. Lee).
1
These authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ajps.2016.05.004
1818-0876/© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
560 asian journal of pharmaceutical sciences 11 (2016) 559–574
Generally, thin films can be referred as a thin and flexible layer Thin film is not a recent formulation, and it was first intro-
of polymer with or without a plasticizer [1]. Since they are thin duced in late 1970 to overcome swallowing difficulties exhibited
and flexible by their nature, it can be perceived to be less ob- by tablets and capsules [15]. Various names of thin films ap-
trusive and more acceptable by the patient [2]. The thin film peared, such as oral film (oral thin film), oral soluble film, wafer,
is polymeric matrices that meet many requirements for being oral strip, orodispersible film (ODF), buccal film, mucoadhesive
used efficiently as a drug release platform [3]. Fundamen- film, ophthalmic film, and transmucosal film.While several films
tally, thin films are excellent candidates for targeting sensitive are designed to be dissolved quickly in the oral cavity for the
site that may not be possible with tablets or liquid formula- absorption of a drug in the gastrointestinal cavity (oral and oral
tions [4]. Thin films have shown the capabilities to improve the soluble, or orodispersible films), some are prepared to deliver
onset of drug action, reduce the dose frequency and enhance a drug at the site of administration (e.g., buccal, sublingual and
the drug efficacy [3]. Similarly, thin films may be useful for elimi- ophthalmic thin films). Drugs with high mucosal permeability
nating side effects of a drug and reducing extensive metabolism have been known to be suitable for buccal and sublingual de-
caused by proteolytic enzymes [5,6]. Ideal thin films need to livery with films [18]. Likewise, ophthalmic thin films are
exhibit desirable features such as sufficient drug loading ca- generally applied to treat diseases of the anterior segment such
pacity, fast dissolution rate or long residence time at the site as conjunctivitis, glaucoma and chronic dry eye syndromes [5,19].
of administration, and acceptable formulation stability. They A film that readily dissolves in the oral cavity is generally
should also be non-toxic, biocompatible and biodegradable [7,8]. termed as orodispersible film according to European Medi-
Compared with the existing traditional dosage forms, it cines Agency (EMA) or simply soluble film according to FDA
stands out to be superior in terms of enhanced bioavailability, [3]. Usually, fast dissolving oral films are ultra-thin film (50–
high patient compliance, and patent extension of active phar- 150 μm) having size of postage stamp, which dissolves within
maceutical ingredients (API) [9]. Furthermore, thin film a minute in the oral cavity after being in contact with the saliva,
formulations offer several advantages, including (a) conve- resulting in quick absorption and instant bioavailability of the
nient administration through non-invasive routes, (b) ease of drugs [20,21]. Drugs loaded in buccal adhesive films are ab-
handling during manufacture and transportation, and (c) cost- sorbed directly via buccal mucosa, which delivers the drug to
effectiveness in the development of formulations [8,10,11]. The the systemic circulation after their absorption [22]. Likewise,
availability of a wide array of suitable polymers and the para- wafer is frequently mentioned as paper-thin polymeric films
digm shift in manufacturing technology have made possible employed as carriers for pharmaceutical agents. This innova-
to develop a wide range of thin films [12]. Therefore, a thin film tive dosage form is taken orally but does not require water to
is gaining popularity and acceptance in the pharmaceutical swallow for the absorption of a drug [23]. Orodispersible films
arena as a novel drug delivery dosage form. should not be misunderstood with buccal films designed for
Substantial efforts have been made to formulate polymeric staying longer on the cheek mucosa [24]. Therefore, different
thin films that are administered generally via buccal, sublin- types of films should be distinguished accurately to prevent
gual, ocular and skin routes [13,14]. Among different routes, the possible misinterpretations.
use of thin films for delivering medicine into sublingual or buccal
mucosa has drawn immense interest in recent years [15]. Mean-
while, ophthalmic films are currently developed for overcoming 3. Advantages of thin films as an emerging
the ocular barriers and preventing loss of drugs through the dosage form
lacrimal drainage system [16]. Controlling compositions of
polymers of different grades has facilitated the modification of 3.1. Advantages over conventional dosage forms
key characteristics of thin films such as drug release rate,
mucoadhesive properties, mechanical strength and other related A thin film dissolves rapidly than other conventional dosage
properties. Additionally, various inactive components can be in- forms [25]. Thin films are less friable and easy to carry dosage
cluded such as fillers, plasticizer, saliva stimulating agent, form compared to commercialized orally fast disintegrating
colorants, and sweeteners for improving aesthetic characteris- tablets, which need special packing. Likewise, a single dose of
tics. Many pharmaceutical companies are fascinated by the strip can be carried individually without requiring the sec-
appealing features of thin films, and as a result they have already ondary container [26,27]. It is very important to address the
patented various technologies for producing thin films [17]. poor stability of liquid dosage forms, especially the aqueous
Currently, a significant amount of original works and patents formulations. Unlike the thin films, there is a need for great
can be found in literature, but still there is a need for exten- care during accurate measurement of the amount and shaking
sive studies to optimize the performance of thin films the bottle every time before administration may contribute to
accurately. The lack of appropriate guidance for the manufac- less acceptance by the patients [3]. Conventional ophthalmic
ture, characterization and quality control of the thin films has drug delivery systems such as eye drops or solutions are
sought the need of adequate studies in this area from the phar- commonly used but they are limited in their ability to provide
maceutical viewpoint. Therefore, this paper will contribute to high ocular drug bioavailability and sustained duration of action
give insights on understanding the critical quality attributes [28]. Ophthalmic thin films can be used to improve the drug
and characterization methods with the aim to enhance the per- delivery to the eye. In contrast to transdermal patch, the trans-
formance of thin films. dermal film is less associated with skin irritation due to less
asian journal of pharmaceutical sciences 11 (2016) 559–574 561
occlusive properties that improve the water vapor perme- different molecular weights, and thus the appealing and glossy
ation through the skin and do not leave sticky sensation on films could be obtained with the gelatin having a high molecu-
the site of application [29,30]. lar weight. Pullulan is frequently used for producing a thin film
with great solubility, high mechanical strength and they are stable
3.2. Clinical advantages over a wide range of temperatures.The blending of chitosan and
high methoxy pectin (HMP) or low methoxy pectin (LMP) re-
Patients show preference toward thin film due to its appella- sulted in a thin film exhibiting an excellent mechanical strength.
tive form and ease of administration [17]. Furthermore, oral The film forming polymers such as hydroxypropyl cellulose (HPC),
dissolving film is extensively useful for pediatric, geriatric, and methyl cellulose, and carboxymethyl cellulose (CMC) produce
psychiatric patients since it is easy to administer and avoid a thin film with less water vapor barrier due to hydrophilic nature
the risk of choking or suffocation, thus ensuring patient safety which aids in water retention [15].
[22]. Ophthalmic films have been known to enhance the re- In one study, a fast-dissolving film of triclosan was pre-
tention time of a drug, and thereby the absorption of the pared using different grades of hydroxypropyl methylcellulose
drug was greatly improved from the anterior segment of the (HPMC) named as Methocel E3, Methocel E5, and Methocel
eye [31]. Moreover, the polymeric thin films can also be ben- E15 Premium LV as a primary film former. The result demon-
eficial for bedridden and non-cooperative patients as they can strated that Methocel E5 Premium LV at the concentration of
be administered easily and hardly spit out. A thin film is useful 2.2% w/v produced films with excellent film properties [37].The
in cases where a rapid onset of action is required, such as in in vitro residence time of the film made from Carbopol® 934P
motion sickness, sudden episodes of allergic attack or cough- and HPMC E15 was almost double than the films containing
ing, bronchitis or asthma [22]. only HPMC E15. Additionally, it was observed that the com-
bined polymers were more resistant to breakage [11]. Cilurzo
et al. reported the use of maltodextrins (MDX) with low dex-
4. Major limitations of thin films trose content as a film forming polymer for the preparation of
oral fast-dissolving films of an insoluble drug, piroxicam. Despite
the decrease in film ductility due to the loading of the drug as
Use of thin films is sometimes limited largely due to low drug
a powder, the produced film exhibited satisfactory flexibility
loading capacity for a less potent drug given at high dose [10].
and resistance to elongation along with rapid dissolution [38].
Thin films are usually hygroscopic in nature. Thus, special
Similarly, oral dissolving films of granisetron HCl manufac-
precaution should be taken for their longer preservation [4].
tured using HPMC and pullulan illustrated the effect of increasing
Combining more than one drug concomitantly is a very chal-
polymer concentration on mechanical properties and physi-
lenging task in oral film formulation because both the dissolution
cal properties of films. Pullulan with 40–45% concentration was
rate as well as the disintegration time are hindered by the co-
not able to produce films with good strength whereas the HPMC
administration of a drug in oral films [32].The difficulty to obtain
used in 40% concentration yielded the film which was diffi-
a high degree of accuracy with respect to the amount of drug
cult to peel. Likewise, the film stickiness increased when the
in individual unit dose of the film can lead to therapeutic failure,
concentration of HPMC was beyond 50% [39].
non-reproducible effects and sometimes toxic effects to the
Mucoadhesive films are thin and flexible retentive dosage
patient [33]. Preparing oral film formulation is concerned with
forms, and release drug directly into a biological substrate.They
the issues of requiring excessive time for drying. It takes around
facilitate in extending residence time at the application site
one day for the complete drying at room temperature, which
leading to prolonged therapeutic effects [40]. Majority of the thin
notably decreases the rate of production of films. Since it is
film having mucoadhesive properties are hydrophilic in nature
not recommended to use hot air oven for thermolabile drugs,
and undergoes swelling and form a chain interaction with the
an alternative process of drying should be explored [22].
mucin [11]. Among the several studied polymers, the most com-
pelling mucoadhesion properties are exhibited by chitosan,
hyaluronan, cellulose derivatives, polyacrylates, alginate, gelatin
5. Polymers for the preparation of thin films and pectin [41]. Compared with non-ionic polymers, the cat-
ionic and anionic polymers facilitate strong interaction with
Polymers are the backbone of film formulations and various mucus [42]. Anionic polymers are well characterized due to the
polymers are available for the preparation of thin films [34]. existence of carboxyl and sulfate functional groups, which
The polymers can be used alone or in combination with other create the negative charge at pH values surpassing the pKa
polymers to achieve the desired film properties. The poly- of the polymer. As an example, sodium carboxymethyl cellu-
mers employed should be non-toxic, non-irritant, and absence lose (NaCMC) and polyacrylic acid (PAA) exhibit excellent
of leachable impurities is required. Water-soluble polymers are mucoadhesive properties because of bond formation with the
used as film formers to produce a thin film with rapid disin- mucin [43].Thiomers, i.e. polymer containing thiol group, stand
tegration, good mechanical strength, and good mouthfeel out to enhance mucoadhesion because they are able to interact
effects. Both natural and synthetic polymers are used for film with the mucin through the formation of disulfide linkages.
preparation [20,35]. The list of polymers commonly used in the The process of ‘thiloation’ is possible with many polymers,
manufacture of polymeric films, with additional descriptions using amide-coupling chemistry, where the aqueous solvent
and properties, is depicted in Table 1. systems are used [44]. Eudragit displayed promising mucoadhesive
Availability of diverse polymers allows imparting specific prop- properties when used alone or in combination with other hy-
erties in the thin films. For instance, gelatins are available in drophilic polymers. Films, prepared from the propranolol HCl,
562 asian journal of pharmaceutical sciences 11 (2016) 559–574
Table 1 – Properties and key findings of representative polymers used for preparation of thin film formulations.
Polymer Properties Key findings References
Hydroxypropyl • White, creamy, odorless, and tasteless powder • Film forming ability at 2–20% concentrations [3,11,17,36]
methylcellulose • Mw 10,000–1,500,000 • Generally used for controlled and/or delayed
(HPMC) • Soluble in cold water, but insoluble in chloroform release of the drug substance
and ethanol • Initial burst drug release followed by slow or
• Viscosity (η) 3–100,000 mPa·s sustained drug release diffusion observed in buccal
• Non-ionic polymer with moderate bioadhesive system of nicotine hydrogen tartrate
mucoadhesive properties
• Solutions are stable at pH 3.0 to 11.0
Carboxymethyl • White, odorless powder • Improved the residence time of HPC and sodium [3,11,17,36]
cellulose (CMC) • Mw 90,000–700,000 alginate films
• Easily dispersed in water to form a clear or • Good compatibility with starch forming
colloidal solution single-phase polymeric matrix films with improved
• η 5–13,000 mPa·s (1% aqueous solution) mechanical and barrier properties
• High swelling properties • The enzymatically modified CMC has good film
• Good bioadhesive strength forming property
Hydroxypropyl • White to slightly yellow colored, odorless, inert • Used to replace synthetic polymers or HPMC in a [3,11,17,36]
cellulose (HPC) and tasteless powder polymer matrix with modified starch to improve
• Mw 50,000–1,250,000 solubility
• Soluble in cold and hot polar organic solvents • It has a good film forming property and 5% (w/w)
such as absolute ethanol, methanol, isopropyl solution is generally used for film coating
alcohol and propylene glycol • Zero-order release kinetics of lidocaine and
• η 75–6500 mPa·s depending upon the clotrimazole associated with erosion square-root of
polymer grade time release kinetics of lidocaine
• Moderate mucoadhesive properties
Poly (vinyl • Wide range of solubility • Blending of PVP with PVA and HPMC improves film [3,11]
pyrrolidone) • Non-ionic forming ability
(PVP) • High swelling properties • Blended with ethyl cellulose and HPC produces
• Used as co-adjuvant to increase mucoadhesion films with increased flexibility, softer and tougher
properties
• Different ratios of PVP-alginate blends can be used
to design drug controlled release
• As film-forming polymer exhibited non-Fickian
release of ketorolac and progesterone
Poly (vinyl • White to cream-colored granular powder • Very flexible films [3]
alcohol) (PVA) • Mw 20,000–200,000 • Mainly used in ophthalmic polymeric preparations
• Water soluble synthetic polymer at concentration of 3–5%
• Non-ionic polymer • Higher elongation at break values
• Moderate mucoadhesive properties
Poly (ethylene • Non-ionic polymer • Optimization of tear resistance, dissolution rate, [3,11]
oxide) (PEO) • High mucoadhesion with high molecular weight and adhesion tendencies of film by combining low
Mw PEO, with a higher Mw PEO and/or with
cellulose
• Films with good resistance to tearing, minimal or
no curling
• Pleasant mouth feeling with no sticky or highly
viscous gel formation
Pullulan • White, odorless, and tasteless powder • Blending with sodium alginate and/or CMC may [3,17]
• Mw 8000–2,000,000 synergistically enhance the properties of the film
• Soluble in hot as well as cold water • Pullulan–HPMC films have improved thermal and
• η 100–180 mm2/s (10% aqueous solution at 30 °C) mechanical properties
• Contain > 6% w/w of moisture • 5–25% (w/w) solution forms flexible films
• Stable film with less permeability to oxygen
Pectin • A yellowish white, odorless powder with • Not very useful for fast dissolving films, but [3,17]
mucilaginous taste modified pectins yielded films with fast
• Mw 30,000–100,000 dissolution rates
• Soluble in water but insoluble in most of the • Good film forming capacity at low temperature
organic solvents • Brittle and do not have a clear plastic deformation
• Strong mucoadhesive properties
Chitosan • White or creamy powder or flakes, and odorless • Excellent film forming ability [11,36]
• Obtained after partial deacetylation of chitin • Chitosan enhances the transport of polar drugs
• Biocompatible and biodegradable across epithelial surfaces
• Sparingly soluble in water; practically insoluble in • Possesses cell-binding activity due to polymer
ethanol (95%), other organic solvents, and neutral or cationic polyelectrolyte structure that binds to the
alkali solutions at pH above approximately 6.5 negative charge of the cell surface
(continued on next page)
asian journal of pharmaceutical sciences 11 (2016) 559–574 563
Table 1 – (continued)
Polymer Properties Key findings References
Sodium alginate • Occurs as a white or buff powder, which is • Used as immobilization matrices for cells and [11,36]
odorless and tasteless enzymes, controlled release of bioactive substances
• Purified carbohydrate product extracted from • Excellent gel and film forming properties
brown seaweed by the use of dilute alkali • Compatible with most water-soluble thickeners
• Insoluble in other organic solvents and acids and resins
where the pH of the resulting solution falls
below 3.0
• η 20–400 Cps (1% aqueous solution)
• Anionic with high mucoadhesive properties
• Safe, biodegradable and non-allergenic
• Rapid swelling and dissolution in water
Carrageenan • An anionic polysaccharide, extracted from the red • Potential to act as protein/peptide stabilizer by [6,11,36]
seaweed Chondrus crispus steric stabilization
• Three structural types exist: Iota, Kappa, and • It is compatible with most nonionic and anionic
Lambda, differing in solubility and rheology water soluble thickeners
• The sodium form of all three types is soluble in • Solutions are susceptible to shear and heat
both cold and hot water degradation
• The best solution stability occurs at pH 6 to 10
• Moderate mucoadhesive properties
Gelatin • A light amber to faintly yellow colored powder • It has a very good film forming ability [17]
• Mw 15,000–250,000 • Useable for preparation of sterile film, ophthalmic
• Soluble in glycerin, acid, alkali and hot water film, and sterile sponge
• η 4.3–4.7 mPa·s (6.67% (w/v) aqueous solution
at 60 °C)
• Moisture content 9–11% (w/w)
Eudragit RS100, and triethyl citrate (plasticizer), demonstrated have been employed for polymeric thin film manufacturing are
mucoadhesive force three times greater than the film prepared described below in detail:
with chitosan as the mucoadhesive polymer [11]. Juliano et al.
prepared a buccoadhesive films consisting of alginate and/or 6.1. Solvent casting
HPMC and/or chitosan either as a single polymer or in a com-
bination of two. Basically, they aimed the films to release the Among several techniques of film manufacturing, solvent
chlorhexidine diacetate in a controlled manner. HPMC was not casting is feasible, preferable and undoubtedly widely used
able to prolong the chlorhexidine release as more than 80% of method mainly due to the straightforward manufacturing
the drug was released within only 30 min. However, chlorhexidine process and low cost of processing. The manufacturing pro-
incorporated in alginate and alginate/chitosan-based films showed cedure of thin films with the solvent casting method along with
that only 30–35% of the drug was released in 30 min; hence, this the quality control parameters in each step is illustrated in Fig. 1.
polymeric system is beneficial for prolonged drug release [45]. The rheological properties of the polymeric mixture should be
In common terms, polymers are understood as excipi- taken into account since they affect the drying rate, the film
ents, but it has become an essential component while designing
and formulating thin films. Therefore, understanding the prop-
erties of polymers such as chemistry, rheology, and physico-
chemical properties of polymer seems to be imminent for
maximizing their uses to develop a thin film. The selection of
appropriate polymer during the development of polymeric thin
films may be critical; thereby, several points should be con-
sidered according to the requirements. Therefore, it is imperative
to consider the appropriate polymer for producing a thin film
with a better performance that assures high therapeutic success.
Fig. 2 – Commercial manufacturing of film based on solvent-casting (reproduced from Ref. [22]).
thickness, the morphology as well as the content uniformity method to solvent casting for the preparation of the film, es-
of the films [26]. The mixing process could introduce the air pecially useful when no organic solvent system is required [10].
bubbles into the liquid inadvertently; therefore, de-aeration is However, only few literature has reported the use of hot-melt
a pre-requisite to obtain a homogeneous product [17]. After extrusion for the preparation of polymeric thin films [11]. HME
casting the solution into a suitable substrate, they are left for is a process of shaping a mixture of polymers, drug sub-
drying to allow the solvent to evaporate, which just leaves a stance, and other excipients into a film by melting all the
polymeric film with a drug on it [2]. components [3]. Eventually, the films are cut into a particular
After the complete drying of the film, it is cut into suitable shape and dimensions [6]. In this method, a mixture of phar-
shape and size depending upon the required dosage of the formed maceutical ingredients is molten and then charged through
strip. In the majority of the cases, the strips are rolled and stored an orifice (the die) to obtain homogeneous matrices [11]. Since
for a certain time before cutting, which is known as ‘rollstock’ APIs are subjected to operation at high temperature with
in an industry. However, a film should not be exposed for too complete absence of solvents, this method is not suitable for
long time since it is prone for being damaged. If possible, it should thermos-labile APIs [17]. The practical steps of HME are out-
be cut and packed immediately after the preparation to keep lined as follows [53]:
its stability [17]. Several advantages such as better physical prop-
erties, easy and low cost processing, and excellent uniformity (1) Feeding of the components to the extruder through
of thickness are observed with the film obtained by solvent- a hopper,
casting [50]. However, this process suffers from some limitation. (2) Mixing, grinding, and kneading,
For instance, a polymeric thin film prepared by solvent casting (3) Flowing the molten and blended mass to the die, and
method was brittle upon storage, as marked by decrease in the (4) Extruding the mass through the die and further down-
percent elongation due to evaporation or loss of the residual stream processing.
solvent in the film over time [51]. Another issue under scrutiny
associated with this method is the requirement of using organic The equipment for the process of HME is illustrated in Fig. 3,
solvents. The presence of organic solvent system is a serious which consists of the hopper, extruder, film die, and roller. The
problem because it causes a hazard to health and environ- extruder contains one or two rotating screws (co-rotating or
ment. As a result, strict regulations have been adopted by many counter rotating) inside a static cylindrical barrel. The barrel is
countries regarding the use of an organic solvent [11]. often manufactured in sections to shorten the residence time
Translating the production of films from a bench scale to of the molten material.The sectioned part of the barrel is either
production scale is one of the biggest challenges because many
factors such as heating, mixing speed, and temperature could
bring variability in quality, and consistent formation of films
in commercial scale may not be possible. Therefore, suffi-
cient endeavor should be invested to optimize the various
parameters such as the speed of casting, drying time, and final
thickness of the dried strip, which may affect the production
of films from commercial scale output [17]. Fig. 2 depicts the
machine that is used for a large-scale production of film based
on solvent casting technique.
HME is a versatile method adopted for the manufacture of gran- Fig. 3 – Hot-melt extrusion system for the preparation of
ules, tablets, pellets [52], and also thin films [38]. It is a substitute films (reproduced from Ref. [22]).
asian journal of pharmaceutical sciences 11 (2016) 559–574 565
bolted or clamped together. Similarly, the end portion of the barrel several reasons, such as coating mass properties, like viscos-
is connected to the end-plate die, which is interchangeable de- ity or density, which are inherently influenced by the amount
pending upon the required shape of the extruded materials [1]. and characteristics of the processed drug substances. With
With regard to the advantages of HME, it produces a drug regard to the conventional method of film preparation, it may
in the form of solid dispersion or solution, which could improve be very challenging to ensure the same dosage accuracy in the
solubility of poorly soluble drugs [51]. However, at elevated tem- individual units [3]. To summarize, printing a drug on dosage
perature, there is a high chance of recrystallization of API in form is the latest intervention for film preparation and it has
the polymer blend as the temperature drop. Using highly viscous become a powerful tool to manufacture dosage form with ex-
polymeric substance or increasing the amount of plasticizer cellent uniformity, speed-ability, and stability. Representing
can prevent this problem. Another issue of HME is the “Die swell printing technologies that have been used for preparation of
phenomenon,” i.e. an increase in the cross-section of the film polymeric thin films are discussed below.
after ejection from the die depending on the viscoelastic char-
acteristics of polymers. This is due to the polymer withstanding 6.3.1. Inkjet printing
high energy kneading and high shear force during extrusion. Inkjet printing is the recently developed technology, which is
This problem can be prevented by slowing the speed of screw characterized by its versatility, accuracy, repeatability and rela-
operation or by gently mixing molten mass for a long time tively inexpensive method that deposits small volumes of
instead of high shear kneading for a short duration [54]. Unlike solution in films. Inkjet printing is extensively applicable for
solvent casting, this method avoids the need of organic solvent; the preparation of low dose medicines and also offers an op-
hence, they are proven to be environment friendly [2]. portunity to manufacture personalized medicines [58].
Inkjet technology is usually divided into mainly two types:
6.3. Printing technologies (a) continuous inkjet printing (CIP) and (b) drop on demand
(DoD) printing. Both are different in their printing process by
Novel methods such as 3D printing could be used for manu- which the drops are generated. In the case of CIP, there is a
facturing polymeric thin films. It could potentially be a platform consistent ejection of a liquid through an orifice (nozzle), and
for producing the dosage form beneficial to the individual it breaks up into a stream of drops under the force of surface
patient. This possibly will resolve the issue of the pharmaceu- tension. For the continuous production of a stream of ink-
tical industry and pharmacies to meet the future demand of drops, the individual drop should be ‘steered’ to a particular
customized medicine [55]. The printing technologies are in- landing site to produce a printed pattern. This is possible by
creasingly gaining popularity because of its flexibility and cost- applying an electric charge on some of the drops that deflect
effectiveness. From the viewpoint of pharmaceutical industry, the stream from the main axis under an electrostatic field. On
printing technologies are commonly in practice for identify- the other hand, ejection of the liquid from the printhead occurs
ing or labeling of the pharmaceutical dosage forms, particularly in drop-on-demand printing only when a drop is needed. The
to optimize the product to be readily identified and to prevent production of individual drop takes place rapidly under the re-
counterfeit production. However, this approach has recently sponse of trigger signal. A DoD printhead consists of multiple
been adopted for the drug loading of pharmaceutical dosage nozzles (ranges from 100 to 1000, even though specialist
forms [3]. The examples include the use of off-the-shelf con- printhead may have a single nozzle). The drop ejection occurs
sumer inkjet printers in which drug-loaded inks are deposited due to the kinetic energy of drops generated from the source
to yield accurately dosed units of pharmaceutical ingredi- located in the printhead nearby to each nozzle [59].
ents. In addition, a combination of inkjet and flexographic The uniform distribution and dose accuracy of the drug sub-
technologies has been practiced as well [55]. The inkjet print- stance in the film rely upon the density or viscosity of the ink
ing was used for printing of API on different substrate, whereas (drug substance solution or suspension), which determine the
the flexographic printing was employed to coat the drug loaded- printability characteristics [3]. Janßen et al. demonstrated
substrate with a polymeric thin film [56]. the deposition of low doses of salbutamol sulfate onto com-
Loading of drug substances into transdermal patches is pos- mercially available starch-based film using conventional desktop
sible via screen printing and pad printing; however, pad printing printers [10]. However, inkjet printing is not applicable for high-
is limited by the low speed of production. In recent years, inkjet throughput industrial production, instead using of flexographic
printing has made inroads for preparation of film formulation printing is regarded more suitable for industrial preparation.
as a safe and accurate method to produce dosage form of potent
drug administered at low dose [57]. Preparation of multiple layers 6.3.2. Flexographic printing technology (FPT)
can be done by adding a second printing layer on the top of FPT is a process that transfers active pharmaceutical ingredi-
the first with or without an intermediate base film layer. Further, ent into thin films gently via contact printing [10]. The
the printed layer would be shielded by a second base film layer. flexographic printing is a rotary printing process as depicted
This will result in modified drug release profiles and protect in Fig. 4, where ink consisting of drug substance solution and
the ink layer from detachment or mechanical stress during pro- suspension is measured by an anilox roller, then are trans-
cessing like cutting or packaging area [55]. ferred to a printing cylinder that prints the film after unwinding
Regardless of the various types of printing technique the daughter roll [3]. It is useful for heat sensitive products
used, all of them contribute to producing a film with more ho- like proteins and peptides. As the mixing and drying of film
mogeneous distribution and accurate dosage of the drug formulation are processed before introducing the drug, the prob-
throughout the films. The dose accuracy and uniform distri- lems such as loss of activity of API can be prevented. The
bution of the drug substances in the films are accounted for production efficiency is also high considering the production
566 asian journal of pharmaceutical sciences 11 (2016) 559–574
Fig. 4 – Schematic overview of flexography technology for the preparation of films (reproduced from Ref. [57]).
rate of 530 oral films per minute; hence, this process could be m (Batch ) × m ( API film) × 10, 000
H ( μm ) = +f (1)
expanded to scale-up production [6]. No effect on the me- ρ (Batch ) × m ( API) × A (Film )
chanical properties of polymeric thin films upon printing drug
solutions was witnessed using flexographic printing [57]. In a where API is active pharmaceutical ingredient, m is mass, ρ
study, Janßen et al. found that it was possible to dispense is density, and A is area expressed in g, g/cm 3 , and cm 2
tadalafil and rasagiline mesylate solution onto hydroxypropyl respectively.
methylcellulose films using flexographic printing. The intro- The weight variation is generally determined to ensure that
duction of hydroxypropyl cellulose appeared to reduce drug each film contains the consistent amount of a drug without
crystallization after printing. However, the main drawbacks of significant deviation. It is calculated by weighing the indi-
flexography are relatively low resolution, high chances of con- vidual film and the average weights of specified films
tamination, and the need to prepare a print roller, which is not respectively. The average weight of film is subtracted from the
suitable for large scale production [10]. individual weight of patches. The mean ± SD values are cal-
culated for all the formulations. A large variation in weight
signifies the inefficiency of the method applied and high
chances are there for non-uniformity in drug content [12].
7. Quality issues of thin films
7.2. Mechanical and physical properties
For being regarded as an ideal thin film, a film should have ad-
equate flexibility, softness, elasticity, and good physico- Polymeric films should possess enough tension so that it can
chemical stability. Therefore, all these parameters should be be ejected easily from the pouch, rolled up after casting, and
considered carefully while developing film to ensure its effi- peeled from the release liner, but should not be too flexible
cient performance. Characterization of a film is a pre-requisite because greater elongation during cutting and packaging might
that may include assessing properties such as mechanical cause variation in film amount resulting in non-uniformity of
strength, hydration, in vitro release and surface morphology. API amount per film [49,64]. Mechanical properties of films can
The following section outlines the various critical quality at- be defined in terms of Young’s modulus, percent elongations,
tributes affecting film properties and commonly used in vitro tensile strength and tear resistance [64,65]. It has been known
methods for film characterization. that soft and weak polymers exhibit low tensile strength, low
elongation at break and low Young’s modulus, whereas the hard
7.1. Thickness and weight variation and tough polymer have a high tensile strength, high elonga-
tion at break and high Young’s modulus [11]. Additionally, the
The measurement of thickness is necessary as it directly mechanical properties of films are affected by the method of
correlates with the amount of drug in the film. In addition, an manufacturing and the formulation. Some general behaviors
appropriate thickness is required for the comfortable admin- of films observed from stress—strain curves are shown in Fig. 5
istration of films. For instance, the ideal thickness of buccal [6]. The concentration and types of the polymers are largely
films should be in the range of 50 to 1000 μm [12]. Generally, responsible for producing a film having good mechanical
the thickness of the formed thin films is measured using Vernier strength and integrity [66]. Likewise, the morphological state
caliper, electronic digital micrometer, screw gauge, or scan- of the film may alter the mechanical strength, e.g. by crystal
ning electron microscopy (SEM) images [60,61]. The amount of growth [64]. Therefore, different factors such as film-forming
plasticizer in the formulation is known to increase the film agent, type of manufacturing process, thickness of film and the
thickness slightly [62]. By inserting m (Batch) – the mass of the type and amount of API in the film have to be considered care-
whole batch, m (API/film) – the drug amount per film, ρ (Batch) fully for controlling the mechanical strength of the film.
– the density of the formulation, m (API) – the total drug amount Blending and cross-linking of two or more polymers are
in the batch and A (Film) – the area of one film in Eq. (1), it is useful methods to improve the mechanical properties of the
possible to calculate the casting thickness (h). A correction factor combined polymeric mix [67]. The film maintains their ap-
f is added due to the shift of actual value of film thickness pearance and integrity after cross-linking, but hardening of the
compared to the set values. A shift behavior is defined before- film surface can occur [68]. Consistent with this observation,
hand over different coating thicknesses [63]. the mechanical properties of PVA–NaCMC films were greater
asian journal of pharmaceutical sciences 11 (2016) 559–574 567
Fig. 6 – Experimental setup (left) and sample holder for the film preparation (right), where rs indicates radius of samples,
and rp indicates radius of probe. Geometry of cylindrical probes A and B and spherical probe C is shown on the right bottom
(reproduced from Ref. [64]).
568 asian journal of pharmaceutical sciences 11 (2016) 559–574
Slope
Young’s modulus = × 100
Film thickness × Crosshead speed
(4)
7.2.3. Young’s modulus Swelling properties of films are generally observed as the poly-
Young’s modulus or elastic modulus reflects the stiffness or mers employed for making films are hydrophilic [79]. Swelling
elasticity of the films. This indicates resistance to deforma- of the polymers is known to be the fundamental step re-
tion of the films, which can be calculated by plotting the stress quired for bioadhesion [80,81]. In many cases the degree and
strain curve, where slope indicates the modulus, i.e. the greater rate of swelling play a key role in controlling the release of the
the slope, the greater would be the tensile modulus. On the drug. Hence, these parameters can be considered as the indi-
other side, the small slope means lesser tensile modulus and cator for bioadhesive or mucoadhesive potential and drug
deformation [77]. Simply, a film, exhibiting higher tensile release profiles. The testing of swelling is done to measure
strength and greater Young’s modulus values, is the one that polymer hydration [82]. Hydrophilic polymers with different
is hard and brittle with small elongation. Texture analyzer can structures possess a varying degree of swelling based on the
asian journal of pharmaceutical sciences 11 (2016) 559–574 569
showing any erratic absorption profile, resulting in less inter- adherence. So far, the list of drugs formulated in ophthalmic
and intra-individual variability [72]. Oral thin films (OTFs) are films is presented below in Table 3.
comparable to the disintegrating system, which is soaked in saliva The flow of tear across the outer surface of the cornea is
and stick to the site of application. The rate of disintegration continuous, which impedes the drug diffusion leading to low
is rapid, allowing the drug to release and followed by the bioavailability (1–7%) of drugs [108]. Generally, the drug with
oromucosal absorption. Many drugs that undergo degradation higher lipophilicity encounters many problems as it cannot be
in the GI tract are being administered employing this route [98]. dissolved in the aqueous medium of the eye. Since the drug
In context to the commercially marketed product of the oral causes discomfort in the eye, it induces blinking, and there-
thin film, the nutraceuticals and over-the-counter drugs were fore causing washing out of the significant amount of drug.
among the first to be introduced in the market, and included Therefore, the success of the effective development of films
the incorporated active such as vitamins, herbal and non- to be delivered to the eye relies on the comprehensive knowl-
herbal extracts. In 2001, Pfizer introduced a thin film product edge of the drug, the constraints to ocular drug delivery, and
of Listerine Pocketpaks® developed as mouth freshener. The the excipients used. Hence, all these factors should be con-
company Bio-film has been putting an endeavor to develop oral sidered during the formulation of ocular films.
thin films. Not only the pharmaceuticals but they are also using
nutraceuticals such as vitamins, aphrodisiac, energy boost- 9.3. Transdermal route
ers, and appetite suppressor that targets a specific population
of the certain age group. The energy booster consists of various Drug-loaded transdermal films are the alternative to replace
compounds such as caffeine, guarana, and green tea extract the existing transdermal dosage form. Numerous sustained or
to maintain the energy levels [17]. A number of companies have controlled delivery systems have been devised, where a drug
been attempting to develop a drug delivery platform based on is either dissolved or dispersed in the films [71]. The film-
polymeric films. Most of them have already succeeded in ob- forming system has been practiced for the transdermal delivery
taining a film with rapid release along with better therapeutic of steroidal hormones, analgesics, local anesthesia and anti-
outcomes [2]. The companies with their technology platform emetic for systemic effects [109–111].
based on polymeric film are listed in the Table 2. Only a small number of drugs are being designed for the trans-
dermal delivery of films as several factors affect the bioavailability
9.2. Ocular route of drug such as molecular size, polarity, pH of the drug, state of
the skin hydration, subcutaneous reservoir of drug and drug
More than 90% of the marketed ocular formulations are in the metabolism by skin flora [112]. Similarly, the hydration of skin
form of solutions or suspension; however, this conventional is crucial for increasing drug absorption, which is possible by
dosage form lacks in achieving promising therapeutic success using humectant in the film formulation.The physiological factors
[99]. The frequent instillation of eye drops is needed to elicit such as regional skin site, nature of stratum corneum, the
a therapeutic response. This usually leads to patient non- thickness of skin, and density of appendages also influence the
compliance and pulsed administration. Furthermore, the overall outcome of the therapeutic effects of the drug [113].
topically applied drugs to the eye generally enter the sys-
temic circulation via the nasolacrimal duct system, which
possibly cause side effects and systemic toxicity as well [100]. Table 3 – List of drugs used in ocular films.
With the aim of enhancing the ocular bioavailability and over- Active agent in ocular film References
coming the ocular drug delivery barriers, the development of
Acetazolamide [101]
ophthalmic film becomes popular these days [84]. The oph- Timolol maleate [102]
thalmic films result in the reduction of dose frequency, less Ofloxacin [103]
systemic side effects and better therapeutic outcomes. There- Dorzolamide hydrochloride [104]
fore, ophthalmic films could open exciting opportunities as a Levofloxacin [78,105]
delivery platform of therapeutics to replace the traditional Naphazoline HCl [106]
Natamycin [107]
dosage forms for achieving high therapeutic success and patient
572 asian journal of pharmaceutical sciences 11 (2016) 559–574
The thin film may possess better therapeutic efficacy and [5] Kang-Mieler JJ, Osswald CR, Mieler WF. Advances in ocular
patient acceptance compared to the common transdermal drug delivery: emphasis on the posterior segment. Expert
dosage forms such as patches or gels [114]. Due to occlusive Opin Drug Deliv 2014;11:1–14.
[6] Castro PM, Fonte P, Sousa F, et al. Oral films as
properties of transdermal patches, it prevents the perme-
breakthrough tools for oral delivery of proteins/peptides.
ation of water vapor from the skin surface and causes severe J Control Release 2015;211:63–73.
pain at the time of peeling. However, polymeric thin films could [7] Barbu E, Verestiuc L, Nevell TG, et al. Polymeric materials
be a highly promising alternative for transdermal drug deliv- for ophthalmic drug delivery: trends and perspectives.
ery because of the ease of application, flexibility and better J Mater Chem 2006;16:3439–3443.
cosmetic appearance [29]. [8] Achouri D, Alhanout K, Piccerelle P, et al. Recent advances
in ocular drug delivery. Drug Dev Ind Pharm 2013;39:1599–
1617.
[9] Hearnden V, Sankar V, Hull K, et al. New developments and
opportunities in oral mucosal drug delivery for local and
10. Future scope of development
systemic disease. Adv Drug Deliv Rev 2012;64:16–28.
and conclusion [10] Janßen EM, Schliephacke R, Breitenbach A, et al.
Drugprinting by flexographic printing technology – a new
The formulation of a drug into various films has been popular manufacturing process for orodispersible films. Int J Pharm
in recent years. Several undesirable drawbacks associated with 2013;441:818–825.
[11] Morales JO, McConville JT. Manufacture and
conventional dosage forms such as inconvenience of admin-
characterization of mucoadhesive buccal films. Eur J Pharm
istration, lower bioavailability and patient non-compliance have Biopharm 2011;77:187–199.
pushed the development of novel polymeric thin films as a drug [12] Nair AB, Kumria R, Harsha S, et al. In vitro techniques to
delivery platform. This drug delivery platform is being under evaluate buccal films. J Control Release 2013;166:10–21.
surveillance from both start-up and established pharmaceu- [13] Ng YC, Yang Z, McAuley WJ, et al. Stabilisation of
tical companies. The companies strive to design a wide range amorphous drugs under high humidity using
pharmaceutical thin films. Eur J Pharm Biopharm
of thin films for oral, buccal, sublingual, ocular and transder-
2013;84:555–565.
mal routes. Therefore, as an alternative to conventional dosage
[14] Kumari A, Sharma P, Garg V, et al. Ocular inserts –
forms, polymeric thin films are expected to stand out as a advancement in therapy of eye diseases. J Adv Pharm
dosage form to overcome the limitations posed by existing Technol Res 2010;1:291–296.
dosage forms. The film dosage form encounters several chal- [15] Irfan M, Rabel S, Bukhtar Q, et al. Orally disintegrating
lenges during the phases of formulation development and films: a modern expansion in drug delivery system. Saudi
manufacture. Such issues should be addressed to optimize the Pharm J 2015;2015:1–10.
[16] Patel A, Cholkar K, Agrahari V, et al. Ocular drug delivery
overall formulation even after transferring to large-scale manu-
systems: an overview. World J Pharmacol 2015;2:47–64.
facturing. The future looks very promising for the film [17] Dixit RP, Puthli SP. Oral strip technology: overview and
technology in the time to come as new technologies are rapidly future potential. J Control Release 2009;139:94–107.
introduced to prepare thin films. [18] Hao J, Heng PWS. Buccal delivery systems. Drug Dev Ind
Pharm [Internet] 2003;29:821–832.
[19] Rathore KS, Nema RK, Sisodia SS. Timolol maleate a gold
standard drug in glaucoma used as ocular films and
Acknowledgments inserts: an overview. Int J Pharm Sci Rev Res 2010;3:23–29.
[20] Juluru N. Fast dissolving oral films: a novel drug delivery
system. Int J Pharm Sci Rev Res 2013;2:108–112.
This work was supported by the National Research Founda- [21] Siddiqui MDN, Garg G, Sharma PK. A short review on
tion of Korea (NRF) grant funded by the Korean government “a novel approach in oral fast dissolving drug delivery
(MSIP) (No. 2015R1A5A1008958). This work was also sup- system and their patents”. Adv Biol Res 2011;5:291–303.
ported by the Basic Science Research Program through the [22] Amin PM, Gangurde AB, Alai PV. Oral film technology:
National Research Foundation of Korea (NRF) funded by the challenges and future scope for pharmaceutical industry.
Ministry of Education (No. 2015R1D1A1A02062278). Int J Pharm Pharm Res 2015;3:183–203.
[23] Vibhooti P, Preeti K. Wafers technology–a newer approach
to smart drug delivery system. Indian J Res Pharm
Biotechnol 2013;1:428–439.
REFERENCES
[24] Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in
orodispersible films for drug delivery. Expert Opin Drug
Deliv 2011;8:299–316.
[1] Maniruzzaman M, Boateng JS, Snowden MJ, et al. A review [25] Prabhu SC, Parsekar SD, Shetty A, et al. Review article a
of hot-melt extrusion: process technology to review on fast dissolving sublingual films for systemic drug
pharmaceutical products. ISRN Pharm 2012;2012:1–9. delivery. Int J Pharm Chem Sci 2014;3:501–511.
[2] Patel VF, Liu F, Brown MB. Advances in oral transmucosal [26] Russo E, Selmin F, Baldassari S, et al. A focus on
drug delivery. J Control Release 2011;153:106–116. mucoadhesive polymers and their application in buccal
[3] Borges AF, Silva C, Coelho JF, et al. Oral films: current status dosage forms. J Drug Deliv Sci Technol 2015;32:113–125.
and future perspectives: I - Galenical development and [27] Wening K, Breitkreutz J. Oral drug delivery in personalized
quality attributes. J Control Release 2015;206:1–19. medicine: unmet needs and novel approaches. Int J Pharm
[4] Sharma D, Kaur D, Verma S, et al. Fast dissolving oral films 2011;404:1–9.
technology: a recent trend for an innovative oral drug [28] Sultana Y, Jain R, Aqil M, et al. Review of ocular drug
delivery system. Int J Drug Deliv 2015;7:60–75. delivery. Curr Drug Deliv 2006;3:207–217.
asian journal of pharmaceutical sciences 11 (2016) 559–574 573
[29] Guo R, Du X, Zhang R, et al. Bioadhesive film formed [50] Verma S, Kumar N, Sharma PK. Buccal film: an advance
from a novel organic-inorganic hybrid gel for transdermal technology for oral drug delivery. Adv Biol Res 2014;8:260–
drug delivery system. Eur J Pharm Biopharm 2011;79:574– 267.
583. [51] Repka MA, Gutta K, Prodduturi S, et al. Characterization of
[30] Boddupalli B, Mohammed Z, Nath R, et al. Mucoadhesive cellulosic hot-melt extruded films containing lidocaine. Eur
drug delivery system: an overview. J Adv Pharm Technol J Pharm Biopharm 2005;59:189–196.
Res 2010;1:381–387. [52] Crowley MM, Zhang F. Pharmaceutical applications of hot-
[31] Rawas-Qalaji M, Williams CA. Advances in ocular drug melt extrusion: part I. Drug Dev Ind Pharm 2007;33:909–926.
delivery. Curr Eye Res 2012;37:345–356. [53] Chokshi R, Zia H. Hot-melt extrusion technique: a review.
[32] Jadhav YG, Galgatte UC, Chaudhari PD. Challenges in Iran J Pharm Res 2004;3:3–16.
formulation development of fast dissolving oral films. Indo [54] Jani R, Patel D. Hot melt extrusion: an industrially feasible
Am J Pharm Res 2013;3:1746–1751. approach for casting orodispersible film. Asian J Pharm Sci
[33] Perumal VA, Govender T, Lutchman D, et al. Investigating a 2014;10:292–305.
new approach to film casting for enhanced drug content [55] Preis M, Breitkreutz J, Sandler N. Perspective: concepts of
uniformity in polymeric films. Drug Dev Ind Pharm printing technologies for oral film formulations. Int J Pharm
2008;34:1036–1047. 2015;494:578–584.
[34] Renukuntla J, Vadlapudi AD, Patel A, et al. Approaches for [56] Genina N, Fors D, Vakili H, et al. Tailoring controlled-release
enhancing oral bioavailability of peptides and proteins. Int J oral dosage forms by combining inkjet and flexographic
Pharm 2013;447:75–93. printing techniques. Eur J Pharm Sci 2012;47:615–623.
[35] Khairnar GA, Sayyad FJ. Development of buccal drug [57] Anhäuser D, Klein R-P. Verfahren zur Herstellung einer
delivery system based on mucoadhesive polymers. Int J Darreichungsund/oder Dosierungsform für Arzneimittel.
PharmTech Res 2010;2:719–735. LTS Lohmann Therapie-Systeme 1988. EP 0303025.
[36] Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal [58] Alomari M, Mohamed FH, Basit AW, et al. Personalised
bioadhesive drug delivery – a promising option for orally dosing: printing a dose of one’s own medicine. Int J Pharm
less efficient drugs. J Control Release 2006;114:15–40. 2015;494:568–577.
[37] Dinge A, Nagarsenker M. Formulation and evaluation of [59] Daly R, Harrington TS, Martin GD, et al. Inkjet printing for
fast dissolving films for delivery of triclosan to the oral pharmaceutics – a review of research and manufacturing.
cavity. AAPS PharmSciTech 2008;9:349–356. Int J Pharm 2015;494:554–567.
[38] Cilurzo F, Cupone IE, Minghetti P, et al. Fast dissolving films [60] Ali J, Arora S, Ahuja A, et al. Formulation and development
made of maltodextrins. Eur J Pharm Biopharm 2008;70:895– of floating capsules of celecoxib: in vitro and in vivo
900. evaluation. AAPS PharmSciTech 2007;8:E1–E8.
[39] Chaudhary H, Gauri S, Rathee P, et al. Development and [61] Prabhushankar GL, Gopalkrishna B, Manjunatha KM, et al.
optimization of fast dissolving oro-dispersible films of Formulation and evaluation of levofloxacin dental films for
granisetron HCl using Box–Behnken statistical design. Bull periodontitis. Int J Pharm Pharm Sci 2010;2:162–168.
Fac Pharm Cairo Univ 2013;51:193–201. [62] Cao N, Yang X, Fu Y. Effects of various plasticizers on
[40] Landová H, Vetchý V, Gajdziok J. Evaluation of the influence mechanical and water vapor barrier properties of gelatin
of formulation and process variables on mechanical films. Food Hydrocoll 2009;23:729–735.
properties of oral mucoadhesive films using multivariate [63] Preis M, Pein M, Breitkreutz J. Development of a taste-
data analysis. Biomed Res Int 2014;2014:1–9. masked orodispersible film containing dimenhydrinate.
[41] Smart JD, Kellaway IW, Worthington HEC. An in-vitro Pharmaceutics 2012;4:551–562.
investigation of mucosa-adhesive materials for use in [64] Preis M, Knop K, Breitkreutz J. Mechanical strength test for
controlled drug delivery. J Pharm Pharmacol 1984;36:295– orodispersible and buccal films. Int J Pharm 2014;461:22–29.
299. [65] Heng PWS, Chan LW, Ong KT. Influence of storage
[42] Ludwig A. The use of mucoadhesive polymers in ocular conditions and type of plasticizers on ethylcellulose and
drug delivery. Adv Drug Deliv Rev 2005;57:1595–1639. acrylate films from aqueous dispersions. J Pharm Pharm Sci
[43] Fefelova NA, Nurkeeva ZS, Mun GA, et al. Mucoadhesive 2003;6:334–344.
interactions of amphiphilic cationic copolymers based on [66] Liew KB, Tan YTF, Peh KK. Effect of polymer, plasticizer and
[2-(methacryloyloxy)ethyl]trimethylammonium chloride. filler on orally disintegrating film. Drug Dev Ind Pharm
Int J Pharm 2007;339:25–32. 2014;40:110–119.
[44] Cook MT, Khutoryanskiy VV. Mucoadhesion and [67] Dong Z, Wang Q, Du Y. Alginate/gelatin blend films and
mucosa-mimetic materials – a mini-review. Int J Pharm their properties for drug controlled release. J Memb Sci
2015;495:991–998. 2006;280:37–44.
[45] Juliano C, Cossu M, Pigozzi P, et al. In vitro characterization [68] Mathurm M, Gilhotra RM. Glycerogelatin-based ocular
and preliminary in vivo evaluation of buccal polymeric inserts of aceclofenac: physicochemical, drug release
films containing chlorhexidine. AAPS PharmSciTech studies and efficacy against prostaglandin E2-induced
2008;9:1153–1158. ocular inflammation. Drug Deliv 2011;18:54–64.
[46] Kunte S, Tandale P. Fast dissolving strips: a novel approach [69] Jain D, Carvalho E, Banerjee R. Biodegradable hybrid
for the delivery of verapamil. J Pharm bioallied Sci polymeric membranes for ocular drug delivery. Acta
2010;2:325–328. Biomater 2010;6:1370–1379.
[47] El-Setouhy DA, Shakwy N, El-Malak ABD. Formulation of a [70] Karolewicz B. A review of polymers as multifunctional
novel tianeptine sodium orodispersible film. AAPS excipients in drug dosage form technology. Saudi Pharm J
PharmSciTech 2010;11:1018–1025. 2015;2015:1–12.
[48] Low AQJ, Parmentier J, Khong YM, et al. Effect of type and [71] Nesseem DI, Eid SF, El-Houseny SS. Development of novel
ratio of solubilising polymer on characteristics of hot-melt transdermal self-adhesive films for tenoxicam, an
extruded orodispersible films. Int J Pharm 2013;455:138–147. anti-inflammatory drug. Life Sci 2011;89:430–438.
[49] Preis M, Woertz C, Kleinebudde P, et al. Oromucosal film [72] Kaur G, Singh D, Brar V. Bioadhesive okra polymer based
preparations: classification and characterization methods. buccal patches as platform for controlled drug delivery. Int
Expert Opin Drug Deliv 2013;10:1–15. J Biol Macromol 2014;70:408–419.
574 asian journal of pharmaceutical sciences 11 (2016) 559–574
[73] Laohakunjit N, Noomhorm A. Effect of plasticizers on [94] Gandhi RB, Robinson JR. Oral cavity as a site for
mechanical and barrier properties of rice starch film. bioadhesive drug delivery. Adv Drug Deliv Rev 1994;13:43–
Starch/Staerke 2004;56:348–356. 74.
[74] Wong CF, Yuen KH, Peh KK. An in-vitro method for buccal [95] Lesch CA, Squier CA, Cruchley A, et al. The permeability of
adhesion studies: importance of instrument variables. Int J human oral mucosa and skin to water. J Dent Res
Pharm 1999;180:47–57. 1989;68:1345–1349.
[75] Mukherjee D, Bharath S. Design and characterization of [96] Galey WR, Lonsdale HK, Nacht S. The in vitro permeability
double layered mucoadhesive system containing of skin and buccal mucosa to selected drugs and tritiated
bisphosphonate derivative. ISRN Pharm 2013;2013:1–10. water. J Invest Dermatol 1976;67:713–717.
[76] Fulzele SV, Satturwar PM, Dorle AK. Polymerized rosin: [97] Perumal VA, Lutchman D, Mackraj I, et al. Formulation of
novel film forming polymer for drug delivery. Int J Pharm monolayered films with drug and polymers of opposing
2002;249:175–184. solubilities. Int J Pharm 2008;358:184–191.
[77] Yan W, Wen S, Liu J, et al. Determination of reduced [98] Haque SE, Sheela A. Development of polymer-bound
Young’s modulus of thin films using indentation test. Acta fast-dissolving metformin buccal film with disintegrants.
Metall Sin 2009;22:468–480. Int J Nanomedicine 2015;10:199–205.
[78] Gorle AP, Gattani SG. Development and evaluation of ocular [99] de la Fuente M, Raviña M, Paolicelli P, et al. Chitosan-based
drug delivery system. Pharm Dev Technol 2010;15:46–52. nanostructures: a delivery platform for ocular therapeutics.
[79] Peh KK, Wong CF. Polymeric films as vehicle for buccal Adv Drug Deliv Rev 2010;62:100–117.
delivery: swelling, mechanical, and bioadhesive properties. [100] Mahajan HS, Deshmukh SR. Development and evaluation
J Pharm Pharm Sci 1999;2:53–61. of gel-forming ocular films based on xyloglucan. Carbohydr
[80] Roy SK, Prabhakar B. Bioadhesive polymeric platforms for Polym 2015;122:243–247.
transmucosal drug delivery systems – a review. Trop J [101] Tártara LI, Palma SD, Allemandi D, et al. New
Pharm Res 2010;9:91–104. mucoadhesive polymeric film for ophthalmic
[81] Kumria R, Nair AB, Goomber G, et al. Buccal films of administration of acetazolamide. Recent Pat Drug Deliv
prednisolone with enhanced bioavailability. Drug Deliv Formul 2014;8:224–232.
2014;23:471–478. [102] Rathore KS, Nema RK, Sisodia SS. Preparation and
[82] Aburahma MH, Mahmoud AA. Biodegradable ocular inserts characterization of timolol maleate ocular films. Int J
for sustained delivery of brimonidine tartarate: preparation PharmTech Res 2010;2:1995–2000.
and in vitro/in vivo evaluation. AAPS PharmSciTech [103] de Oliveira Fulgêncio G, Viana FA, Silva RO, et al.
2011;12:1335–1347. Mucoadhesive chitosan films as a potential ocular delivery
[83] Baranowski P, Karolewicz B, Gajda M, et al. Ophthalmic system for ofloxacin: preliminary in vitro studies. Vet
drug dosage forms: characterisation and research methods. Ophthalmol 2014;17:150–155.
Sci World J 2014;2014:1–14. [104] Tandale YN, Wagh VD. Formulation and evaluation of
[84] Panomsuk SP, Hatanaka T, Aiba T, et al. A study of the dorzolamide hydrochloride polymeric film. Int J PharmTech
hydrophilic cellulose matrix: effect of drugs on swelling Res 2011;3:1817–1824.
properties. Chem Pharm Bull 1996;44:1039–1042. [105] Dubey BK, Bhowmick M, Joshi A, et al. Design and
[85] Mortazavi SA, Smart JD. An investigation into the role of characterization of sustained release levofloxacin ocular
water movement and mucus gel dehydration in inserts. Int J Biomed Adv 2012;02:453–466.
mucoadhesion. J Control Release 1993;25:197–203. [106] Sharma S, Parvez N, Sharma PK. Formulation and
[86] Eroğlu H, Sargon MF, Öner L. Chitosan formulations for evaluation of naphazoline HCl ocular insert. Glob J
steroid delivery: effect of formulation variables on in vitro Pharmacol 2015;9:97–101.
characteristics. Drug Dev Ind Pharm 2007;33:265–271. [107] Rajasekaran A, Sivakumar V, Karthika K, et al. Design and
[87] Attama AA, Akpa PA, Onugwu LE, et al. Novel evaluation of polymeric controlled release. Eng Technol
buccoadhesive delivery system of hydrochlorothiazide 2010;6:108–115.
formulated with ethyl cellulose- hydroxypropyl [108] Kim YC, Chiang B, Wu X, et al. Ocular delivery of
methylcellulose interpolymer complex. Sci Res Essay macromolecules. J Control Release 2014;190:172–181.
2008;3:343–347. [109] Padula C, Nicoli S, Colombo P, et al. Single-layer
[88] Taylor MJ, Tanna S, Sahota T. In vivo study of a polymeric transdermal film containing lidocaine: modulation of drug
glucose-sensitive insulin delivery system using a rat release. Eur J Pharm Biopharm 2007;66:422–428.
model. J Pharm Sci 2010;99:4215–4227. [110] Ammar HO, Ghorab M, Mahmoud AA, et al. Rapid pain
[89] Tangri P, Khurana S. Basics of ocular drug delivery systems. relief using transdermal film forming polymeric solution of
Int J Res Pharm Biomed Sci 2011;2:1541–1552. ketorolac. Pharm Dev Technol 2013;18:1005–1016.
[90] Adrover A, Pedacchia A, Petralito S, et al. In vitro [111] Aktar B, Erdal MS, Sagirli O, et al. Optimization of
dissolution testing of oral thin films: a comparison biopolymer based transdermal films of metoclopramide as
between USP 1, USP 2 apparatuses and a new millifluidic an alternative delivery approach. Polymers (Basel)
flow-through device. Chem Eng Res Des 2015;95:173–178. 2014;6:1350–1365.
[91] Okamoto H, Taguchi H, Iida K, et al. Development of [112] Tanner T, Marks R. Delivering drugs by the transdermal
polymer film dosage forms of lidocaine for buccal route: review and comment. Ski Res Technol 2008;14:249–
administration I. Penetration rate and release rate. J Control 260.
Release 2001;77:253–260. [113] Mali ADM, Bathe R, Patil M. An updated review on
[92] Hermans K, Van Den Plas D, Kerimova S, et al. transdermal drug delivery systems. Int J Adv Sci Res
Development and characterization of mucoadhesive 2015;1:244–254.
chitosan films for ophthalmic delivery of cyclosporine A. [114] Schroeder IZ, Franke P, Schaefer UF, et al. Delivery of
Int J Pharm 2014;472:10–19. ethinylestradiol from film forming polymeric solutions
[93] Lam JKW, Xu Y, Worsley A, et al. Oral transmucosal drug across human epidermis in vitro and in vivo in pigs.
delivery for pediatric use. Adv Drug Deliv Rev 2014;73:50–62. J Control Release 2007;118:196–203.